Generic placeholder image

Current HIV Research

Editor-in-Chief

ISSN (Print): 1570-162X
ISSN (Online): 1873-4251

Research Article

Diversity of HIV-1 Subtypes and Transmitted Drug-resistance Mutations Among Minority HIV-1 Variants in a Turkish Cohort

Author(s): Rabia Can Sarinoglu*, Uluhan Sili, Ufuk Hasdemir, Burak Aksu, Guner Soyletir and Volkan Korten

Volume 20, Issue 1, 2022

Published on: 18 January, 2022

Page: [54 - 62] Pages: 9

DOI: 10.2174/1570162X19666211119111740

Price: $65

Abstract

Background: The World Health Organization (WHO) recommends the surveillance of transmitted drug resistance mutations (TDRMs) to ensure the effectiveness and sustainability of HIV treatment programs.

Objective: Our aim was to determine the TDRMs and evaluate the distribution of HIV-1 subtypes using and compared next-generation sequencing (NGS) and Sanger-based sequencing (SBS) in a cohort of 44 antiretroviral treatment-naïve patients.

Methods: All samples that were referred to the microbiology laboratory for HIV drug resistance analysis between December 2016 and February 2018 were included in the study. After exclusions, 44 treatment-naive adult patients with a viral load of >1000 copies/mL were analyzed. DNA sequencing for reverse transcriptase and protease regions was performed using both DeepChek ABL single round kit and Sanger-based ViroSeq HIV-1 Genotyping System. The mutations and HIV-1 subtypes were analyzed using the Stanford HIVdb version 8.6.1 Genotypic Resistance software, and TDRMs were assessed using the WHO surveillance drug-resistance mutation database. HIV-1 subtypes were confirmed by constructing a maximum-likelihood phylogenetic tree using Los Alamos IQ-Tree software.

Results: NGS identified nucleos(t)ide reverse transcriptase inhibitor (NRTI)-TDRMs in 9.1 % of the patients, non-nucleos(t)ide reverse transcriptase inhibitor (NNRTI)-TDRMs in 6.8 % of the patients, and protease inhibitor (PI)-TDRMs in 18.2 % of the patients at a detection threshold of ≥ 1 %. Using SBS, 2.3 % and 6.8 % of the patients were found to have NRTI- and NNRTI-TDRMs, respectively, but no major PI mutations were detected. M41L, L74I, K65R, M184V, and M184I related to NRTI, K103N to NNRTI, and N83D, M46I, I84V, V82A, L24I, L90M, I54V to the PI sites were identified using NGS. Most mutations were found in low-abundance (frequency range: 1.0 % - 4.7 %) HIV-1 variants, except M41L and K103N. The subtypes of the isolates were found as follows; 61.4 % subtype B, 18.2 % subtype B/CRF02_AG recombinant, 13.6 % subtype A, 4.5 % CRF43_ 02G, and 2.3 % CRF02_AG. All TDRMs, except K65R, were detected in HIV-1 subtype B isolates.

Conclusion: The high diversity of protease site TDRMs in the minority HIV-1 variants and prevalence of CRFs were remarkable in this study. All minority HIV-1 variants were missed by conventional sequencing. TDRM prevalence among minority variants appears to be decreasing over time at our center.

Keywords: Drug resistance, next-generation sequencing, transmitted drug resistance, HIV-1 infection, Sanger sequencing, antiretroviral treatment.

Graphical Abstract
[1]
UNAIDS. Global HIV&AIDS Statistics, 2020 Fact Sheet. 2020. Available from: https://www.unaids.org/en/resources/fact-sheet
[2]
Turkish Ministry of Health, Public Health Institution, Department of Infectious Diseases, HIV&AIDS Statistics. Available from: https://hsgm.saglik.gov.tr/tr/bulasici-hastaliklar/hiv-aids/hiv-aids-liste/hiv-aids-istatislik.html
[3]
Bbosa N, Kaleebu P, Ssemwanga D. HIV subtype diversity worldwide. Curr Opin HIV AIDS 2019; 14(3): 153-60.
[http://dx.doi.org/10.1097/COH.0000000000000534] [PMID: 30882484]
[4]
Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011; 25(5): 679-89.
[http://dx.doi.org/10.1097/QAD.0b013e328342ff93] [PMID: 21297424]
[5]
Yalçınkaya T, Köse Ş. The distribution of the genetic subtypes of HIV-1. Turk Mikrobiyol Cemiy Derg 2011; 41(3): 116-9.
[http://dx.doi.org/10.5222/TMCD.2011.116]
[6]
Sayan M, Kumbasar Karaosmanoğlu H, Mete B, et al. Molecular epidemiological analysis of HIV-1 pol gene sequences isolated in Istanbul, Turkey. Mikrobiyol Bul 2013; 47(1): 87-97.
[http://dx.doi.org/10.5578/mb.4099] [PMID: 23390906]
[7]
Sayan M, Willke A, Ozgunes N, Sargın F. HIV-1 subtypes and primary antiretroviral resistance mutations in antiretroviral therapy naive HIV-1 infected individuals in Turkey. Jpn J Infect Dis 2013; 66(4): 306-11.
[http://dx.doi.org/10.7883/yoken.66.306] [PMID: 23883841]
[8]
Uluer Biçeroğlu S, Altuğlu I, Nazli Zeka A, Gökengin D, Yazan Sertöz R. HIV-1 subtype distribution determined by phylogenetic analysis of pol gene sequences and automated subtyping tools among HIV-1 isolates from the Aegian Region of Turkey. Mikrobiyol Bul 2014; 48(3): 420-8.
[http://dx.doi.org/10.5578/mb.7609] [PMID: 25052108]
[9]
Yilmaz G, Midilli K, Türkoğlu S, et al. Genetic subtypes of human immunodeficiency virus type 1 (HIV-1) in Istanbul, Turkey. Int J Infect Dis 2006; 10(4): 286-90.
[http://dx.doi.org/10.1016/j.ijid.2005.06.011] [PMID: 16516519]
[10]
Alpsar D, Agacfidan A, Lübke N, et al. Molecular epidemiology of HIV in a cohort of men having sex with men from Istanbul. Med Microbiol Immunol (Berl) 2013; 202(3): 251-5.
[http://dx.doi.org/10.1007/s00430-012-0285-7] [PMID: 23296905]
[11]
Schülter E, Oette M, Balduin M, et al. HIV prevalence and route of transmission in Turkish immigrants living in North-Rhine Westphalia, Germany. Med Microbiol Immunol (Berl) 2011; 200(4): 219-23.
[http://dx.doi.org/10.1007/s00430-011-0193-2] [PMID: 21461764]
[12]
Aibekova L, Foley B, Hortelano G, et al. Molecular epidemiology of HIV-1 subtype A in former Soviet Union countries. PLoS One 2018; 13(2): e0191891.
[http://dx.doi.org/10.1371/journal.pone.0191891] [PMID: 29389951]
[13]
Hassan AS, Bibby DF, Mwaringa SM, et al. Presence, persistence and effects of pre-treatment HIV-1 drug resistance variants detected using next generation sequencing: A Retrospective longitudinal study from rural coastal Kenya. PLoS One 2019; 14(2): e0210559.
[http://dx.doi.org/10.1371/journal.pone.0210559] [PMID: 30759103]
[14]
Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: A global collaborative study and meta-regression analysis. Lancet 2012; 380(9849): 1250-8.
[http://dx.doi.org/10.1016/S0140-6736(12)61038-1] [PMID: 22828485]
[15]
Pham QD, Wilson DP, Law MG, Kelleher AD, Zhang L. Global burden of transmitted HIV drug resistance and HIV-exposure categories: A systematic review and meta-analysis. AIDS 2014; 28(18): 2751-62.
[http://dx.doi.org/10.1097/QAD.0000000000000494] [PMID: 25493601]
[16]
Hofstra LM, Sauvageot N, Albert J, et al. Transmission of HIV drug resistance and the predicted effect on current first line regimens in Europe. Clin Infect Dis 2016; 62(5): 655-63.
[http://dx.doi.org/10.1093/cid/civ963] [PMID: 26620652]
[17]
Aghokeng AF, Monleau M, Eymard-Duvernay S, et al. Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia. Clin Infect Dis 2014; 58(1): 99-109.
[http://dx.doi.org/10.1093/cid/cit627] [PMID: 24076968]
[18]
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2019. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf
[19]
EACS European AIDS Clinical Society. Guidelines version 10.01. 2020. Available from: https://eacs.sanfordguide.com
[20]
Günthard HF, Calvez V, Paredes R, et al. Human immunodeficiency virus drug resistance: 2018 recommendations of the International Antiviral Society-USA Panel. Clin Infect Dis 2019; 68(2): 177-87.
[http://dx.doi.org/10.1093/cid/ciy463] [PMID: 30052811]
[21]
Wittkop L, Günthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): A European multicohort study. Lancet Infect Dis 2011; 11(5): 363-71.
[http://dx.doi.org/10.1016/S1473-3099(11)70032-9] [PMID: 21354861]
[22]
Maartens G, Celum C, Lewin SR. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet 2014; 384(9939): 258-71.
[http://dx.doi.org/10.1016/S0140-6736(14)60164-1] [PMID: 24907868]
[23]
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. 2016. Available from: https://apps.who.int/iris/bitstream/handle/10665/208825/ 9789241549684_eng.pdf;jsessionid=4D7E477F2D9D41C290072ED2B25515A3?sequence=1
[24]
Mbunkah HA, Bertagnolio S, Hamers RL, et al. Low-abundance drug-resistant HIV-1 variants in antiretroviral drug-naive individuals: A systematic review of detection methods, prevalence, and clinical impact. J Infect Dis 2020; 221(10): 1584-97.
[http://dx.doi.org/10.1093/infdis/jiz650] [PMID: 31809534]
[25]
Gianella S, Richman DD. Minority variants of drug-resistant HIV. J Infect Dis 2010; 202(5): 657-66.
[http://dx.doi.org/10.1086/655397] [PMID: 20649427]
[26]
Halvas EK, Aldrovandi GM, Balfe P, et al. Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J Clin Microbiol 2006; 44(7): 2612-4.
[http://dx.doi.org/10.1128/JCM.00449-06] [PMID: 16825395]
[27]
Ávila-Ríos S, Parkin N, Swanstrom R, et al. Next-generation sequencing for HIV drug resistance testing: laboratory, clinical, and implementation considerations. Viruses 2020; 12(6): 617.
[http://dx.doi.org/10.3390/v12060617] [PMID: 32516949]
[28]
Ávila-Ríos S, García-Morales C, Matías-Florentino M, et al. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: A nationally representative 2015 WHO survey. Lancet HIV 2016; 3(12): e579-91.
[http://dx.doi.org/10.1016/S2352-3018(16)30119-9] [PMID: 27658867]
[29]
Derache A, Iwuji CC, Baisley K, et al. Impact of next-generation sequencing defined human immunodeficiency virus pretreatment drug resistance on virological outcomes in the ANRS 12249 treatment-as-prevention trial. Clin Infect Dis 2019; 69(2): 207-14.
[http://dx.doi.org/10.1093/cid/ciy881] [PMID: 30321314]
[30]
Inzaule SC, Hamers RL, Noguera-Julian M, et al. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. Lancet HIV 2018; 5(11): e638-46.
[http://dx.doi.org/10.1016/S2352-3018(18)30177-2] [PMID: 30282603]
[31]
Li JZ, Paredes R, Ribaudo HJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: A systematic review and pooled analysis. JAMA 2011; 305(13): 1327-35.
[http://dx.doi.org/10.1001/jama.2011.375] [PMID: 21467286]
[32]
Milne RS, Silverman RA, Beck IA, et al. Minority and majority pretreatment HIV-1 drug resistance associated with failure of first-line nonnucleoside reverse-transcriptase inhibitor antiretroviral therapy in Kenyan women. AIDS 2019; 33(6): 941-51.
[http://dx.doi.org/10.1097/QAD.0000000000002134] [PMID: 30946148]
[33]
Simen BB, Simons JF, Hullsiek KH, et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 2009; 199(5): 693-701.
[http://dx.doi.org/10.1086/596736] [PMID: 19210162]
[34]
Johnson JA, Li JF, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med 2008; 5(7): e158.
[http://dx.doi.org/10.1371/journal.pmed.0050158] [PMID: 18666824]
[35]
Gibson RM, Schmotzer CL, Quiñones-Mateu ME. Next-generation sequencing to help monitor patients infected with HIV: ready for clinical use? Curr Infect Dis Rep 2014; 16(4): 401.
[http://dx.doi.org/10.1007/s11908-014-0401-5] [PMID: 24585216]
[36]
Moscona R, Ram D, Wax M, et al. Comparison between next-generation and Sanger-based sequencing for the detection of transmitted drug-resistance mutations among recently infected HIV-1 patients in Israel, 2000-2014. J Int AIDS Soc 2017; 20(1): 21846.
[http://dx.doi.org/10.7448/IAS.20.1.21846] [PMID: 28799325]
[37]
Paredes R, Clotet B. Clinical management of HIV-1 resistance. Antiviral Res 2010; 85(1): 245-65.
[http://dx.doi.org/10.1016/j.antiviral.2009.09.015] [PMID: 19808056]
[38]
Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance testing. Infect Genet Evol 2016; 46: 292-307.
[http://dx.doi.org/10.1016/j.meegid.2016.08.031] [PMID: 27587334]
[39]
Parikh UM, McCormick K, van Zyl G, Mellors JW. Future technologies for monitoring HIV drug resistance and cure. Curr Opin HIV AIDS 2017; 12(2): 182-9.
[http://dx.doi.org/10.1097/COH.0000000000000344] [PMID: 28059958]
[40]
Van Laethem K, Theys K, Vandamme AM. HIV-1 genotypic drug resistance testing: Digging deep, reaching wide? Curr Opin Virol 2015; 14: 16-23.
[http://dx.doi.org/10.1016/j.coviro.2015.06.001] [PMID: 26114581]
[41]
Ram D, Leshkowitz D, Gonzalez D, et al. Evaluation of GS Junior and MiSeq next-generation sequencing technologies as an alternative to Trugene population sequencing in the clinical HIV laboratory. J Virol Methods 2015; 212: 12-6.
[http://dx.doi.org/10.1016/j.jviromet.2014.11.003] [PMID: 25445792]
[42]
Noguera-Julian M, Edgil D, Harrigan PR, Sandstrom P, Godfrey C, Paredes R. Next-generation human immunodeficiency virus sequencing for patient management and drug resistance surveillance. J Infect Dis 2017; 216(9)(Suppl. 9): S829-33.
[http://dx.doi.org/10.1093/infdis/jix397] [PMID: 28968834]
[43]
Centers for disease control and prevention. Laboratory testing for the diagnosis of HIV infection, updated recommendations. 2014. Available from: http://stacks.cdc.gov/view/cdc/23447
[44]
Tzou PL, Kosakovsky Pond SL, Avila-Rios S, Holmes SP, Kantor R, Shafer RW. Analysis of unusual and signature APOBEC-mutations in HIV-1 pol next-generation sequences. PLoS One 2020; 15(2): e0225352.
[http://dx.doi.org/10.1371/journal.pone.0225352] [PMID: 32102090]
[45]
Stanford HIV drug resistance database. Major HIV-1 drug resistance mutations. 2020. Available from: https://cms.hivdb.org/prod/downloads/resistance-mutation-handout/resistance-mutation-handout.pdf
[46]
Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4(3): e4724.
[http://dx.doi.org/10.1371/journal.pone.0004724] [PMID: 19266092]
[47]
Los Alamos National Laboratory HIV sequence database. HIV Sequence Compendium 2018, Alignment of HIV-1/SIVcpz Complete Genomes. 2018. Available from: https://www.hiv.lanl.gov/content/sequence/HIV/COMPENDIUM/2018/hiv1dna.pdf
[48]
Los Alamos National Laboratory HIV sequence database, The IQ-Tree phylogenetic reconstruction software. Available from: https://www.hiv.lanl.gov/content/sequence/IQTREE/iqtree.html
[49]
Telele NF, Kalu AW, Gebre-Selassie S, et al. Pretreatment drug resistance in a large countrywide Ethiopian HIV-1C cohort: A comparison of Sanger and high-throughput sequencing. Sci Rep 2018; 8(1): 7556.
[http://dx.doi.org/10.1038/s41598-018-25888-6] [PMID: 29765082]
[50]
Hofstra LM, Sánchez Rivas E, Nijhuis M, et al. High rates of transmission of drug-resistant HIV in Aruba resulting in reduced susceptibility to the WHO recommended first-line regimen in nearly half of newly diagnosed HIV-infected patients. Clin Infect Dis 2017; 64(8): 1092-7.
[http://dx.doi.org/10.1093/cid/cix056] [PMID: 28329390]
[51]
Avila-Ríos S, García-Morales C, Matías-Florentino M, et al. HIV Drug resistance in antiretroviral treatment-naïve individuals in the largest public hospital in Nicaragua, 2011-2015. PLoS One 2016; 11(10): e0164156.
[http://dx.doi.org/10.1371/journal.pone.0164156] [PMID: 27736898]
[52]
Rhee SY, Kassaye SG, Barrow G, Sundaramurthi JC, Jordan MR, Shafer RW. HIV-1 transmitted drug resistance surveillance: Shifting trends in study design and prevalence estimates. J Int AIDS Soc 2020; 23(9): e25611.
[http://dx.doi.org/10.1002/jia2.25611] [PMID: 32936523]
[53]
Sili U, Aksu B, Tekin A, Hasdemir U, Soyletir G, Korten V. Assessment of transmitted HIV-1 drug resistance mutations using ultra-deep pyrosequencing in a Turkish cohort. Curr HIV Res 2018; 16(3): 216-21.
[http://dx.doi.org/10.2174/1570162X16666180910130112] [PMID: 30198436]
[54]
Yalçınkaya T, Köse S. Investigation of HIV-1 primary drug resistance mutations in antiretroviral therapy-naive cases. Mikrobiyol Bul 2014; 48(4): 585-95.
[http://dx.doi.org/10.5578/mb.8321] [PMID: 25492654]
[55]
Sayan M, Sargin F, Inan D, et al. HIV-1 Transmitted drug resistance mutations in newly diagnosed antiretroviral-naive patients in Turkey. AIDS Res Hum Retroviruses 2016; 32(1): 26-31.
[http://dx.doi.org/10.1089/aid.2015.0110] [PMID: 26414663]
[56]
Kuskucu MA, Midilli K, Yemisen M, Abdelkareem A, Ergin S, Tabak F, Eds. Transmitted drug resistance (TDR) prevalence among treatment naive HIV-1 infected patients in Istanbul remained unchanged between 2004 and 2015. J Clin Virol 2015; 70(1): S115.
[57]
Nicot F, Saliou A, Raymond S, et al. Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection. J Clin Virol 2012; 55(2): 107-13.
[http://dx.doi.org/10.1016/j.jcv.2012.06.018] [PMID: 22818969]
[58]
Goodman DD, Zhou Y, Margot NA, et al. Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy. AIDS 2011; 25(3): 325-33.
[http://dx.doi.org/10.1097/QAD.0b013e3283427dcb] [PMID: 21157296]
[59]
Delobel P, Saliou A, Nicot F. Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure. PLoS One 2011; 16: 21655.
[http://dx.doi.org/10.1371/journal.pone.0021655]
[60]
Wensing AM, Calvez V, Silberstein FC. 2019 update of the drug resistance mutations in HIV-1. Recommendations of the international antiviral society-USA panel. Antiviral Medicine 2019; 27(3): 111-21.
[61]
Boffito M, Waters L, Cahn P, et al. Perspectives on the barrier to resistance for dolutegravir + lamivudine, a two-drug antiretroviral therapy for HIV-1 infection. AIDS Res Hum Retroviruses 2020; 36(1): 13-8.
[http://dx.doi.org/10.1089/aid.2019.0171] [PMID: 31507204]
[62]
Bansal V, Metzner KJ, Niederost B, et al. Minority K65R variants and early failure of antiretroviral therapy in HIV-1-infected Eritrean immigrant. Emerg Infect Dis 2011; 17(10): 1966-8.
[http://dx.doi.org/10.3201/eid1710.110592] [PMID: 22000388]
[63]
Bellecave P, Recordon-Pinson P, Papuchon J, et al. Detection of low-frequency HIV type 1 reverse transcriptase drug resistance mutations by ultradeep sequencing in naive HIV type 1-infected individuals. AIDS Res Hum Retroviruses 2014; 30(2): 170-3.
[http://dx.doi.org/10.1089/aid.2013.0130] [PMID: 23895115]
[64]
Pingen M, van der Ende ME, Wensing AM, et al. Deep sequencing does not reveal additional transmitted mutations in patients diagnosed with HIV-1 variants with single nucleoside reverse transcriptase inhibitor resistance mutations. HIV Med 2013; 14(3): 176-81.
[http://dx.doi.org/10.1111/j.1468-1293.2012.01037.x] [PMID: 22989004]
[65]
Van Laethem K, De Munter P, Schrooten Y, et al. No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs. J Clin Virol 2007; 39(1): 43-7.
[http://dx.doi.org/10.1016/j.jcv.2007.02.003] [PMID: 17369083]
[66]
Tekin D, Gokengin D, Onay H, Erensoy S, Sertoz R. Investigation of drug resistance against protease, reverse transcriptase, and integrase inhibitors by next-generation sequencing in HIV-positive patients. J Med Virol 2021; 93(6): 3627-33.
[http://dx.doi.org/10.1002/jmv.26582] [PMID: 33026651]
[67]
Clotet B, Ruiz L, Martinez-Picado J, Negredo E, Hill A, Popescu M. Prevalence of HIV protease mutations on failure of nelfinavir- containing HAART: A retrospective analysis of four clinical studies and two observational cohorts. HIV Clin Trials 2002; 3(4): 316-23.
[http://dx.doi.org/10.1310/67TE-GPXQ-R1LB-BPKG] [PMID: 12187506]
[68]
Sugiura W, Matsuda Z, Yokomaku Y, et al. Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2002; 46(3): 708-15.
[http://dx.doi.org/10.1128/AAC.46.3.708-715.2002] [PMID: 11850252]
[69]
Ode H, Ota M, Neya S, Hata M, Sugiura W, Hoshino T. Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases. J Phys Chem B 2005; 109(1): 565-74.
[http://dx.doi.org/10.1021/jp046860+] [PMID: 16851048]
[70]
Lataillade M, Chiarella J, Yang R, et al. Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing. PLoS One 2012; 7(2): e30118.
[http://dx.doi.org/10.1371/journal.pone.0030118] [PMID: 22355307]
[71]
Tzou PL, Rhee SY, Descamps D. WHO HIVResNet Working Groups. Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance. J Antimicrob Chemother 2018; 75(1): 170-82.
[http://dx.doi.org/10.1093/jac/dkz417]
[72]
WHO. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure and recommendations on early infant diagnosis of HIV. 2018. Available from: https://www.who.int/hiv/pub/guidelines/ARV2018update/en/
[73]
Vitoria M, Hill A, Ford N, et al. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: What are the issues? AIDS 2018; 32(12): 1551-61.
[http://dx.doi.org/10.1097/QAD.0000000000001845] [PMID: 29746295]
[74]
Andreis S, Basso M, Scaggiante R, et al. Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013-2016: Impact on susceptibility to first-line strategies including integrase strand- transfer inhibitors. J Glob Antimicrob Resist 2017; 10: 106-12.
[http://dx.doi.org/10.1016/j.jgar.2017.05.011] [PMID: 28732792]

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy